CD8A and melanoma: To this end, we took advantage of an autologous melanoma model from a patient with primary ICB resistance, consisting of CD8+ tumor infiltrating lymphocytes (TILs) showing positivity for PD-1 and TIGIT, another inhibitory co-receptor, and melanoma cells expressing the corresponding receptor ligands.